Severity
Moderate
FDA Drug recall · Reported September 25, 2019
Failed Impurities/Degradation Specifications
Aurolife Pharma, LLC recalled Fexofenadine Hydrochloride Tablets USP, 180 mg, packaged in a) 30-count carton (NDC 70677… - a moderate-severity action.
Fexofenadine Hydrochloride Tablets USP, 180 mg, packaged in a) 30-count carton (NDC 70677… was recalled by Aurolife Pharma, LLC in September 25, 2019. Reason: Failed Impurities/Degradation Specifications. Check the official notice for the remedy. Verify recall #D-1868-2019 with the FDA Drug before acting.
The recall
Aurolife Pharma, LLC issued this moderate-severity FDA Drug recall-Failed Impurities/Degradation Specifications.
Sourced from official FDA Drug enforcement records. Verify recall #D-1868-2019 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1868-2019) was formally reported on September 25, 2019, with the manufacturer initiating the action on August 23, 2019. It is classified under Moderate severity (Class II), with a current status of Terminated. Aurolife Pharma, LLC is listed as the recalling firm, operating out of Dayton, NJ. Federal records list the affected scope as a) 11,928 cartons; b) 288 cartons.
The documented reason for this recall is: Failed Impurities/Degradation Specifications Distribution data in the federal record shows the product reached: Nationwide in the USA. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
a) 11,928 cartons; b) 288 cartons
Related Recalls
6
5 from same agency
Fexofenadine Hydrochloride Tablets USP, 180 mg, packaged in a) 30-count carton (NDC 70677-0008-2) and b) 15-count carton (NDC 70677-0008-1), sunmark, Distributed by McKesson, One Post Street, San Francisco, CA 94104.
Failed Impurities/Degradation Specifications
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-1868-2019 |
| Date reported | September 25, 2019 |
| Date initiated | August 23, 2019 |
| Recalling firm | Aurolife Pharma, LLC |
| Firm location | Dayton, NJ |
| Affected scope | a) 11,928 cartons; b) 288 cartons |
| Distribution | Nationwide in the USA |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported September 25, 2019. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.